ASML: UBS leaves its recommendation on the stock unchanged

(CercleFinance.com) - UBS reiterates its Neutral opinion on the stock, with an unchanged target price of E710.
This target highlights a potential upside of 14% for the stock.

'We think CMD will be a useful approach to focus on fundamentals, but it is unlikely to move the debate forward in the short term,' says UBS.

It should be noted that the group has updated its 2025 forecast, and is now targeting sales of only 30/35 billion euros, down from 30/40 billion.

Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as decision-making aids for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.